By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Life Care NewsLife Care NewsLife Care News
  • Home
  • Business
    • Business
  • News
  • Tech
  • Entertainment
  • Health
  • Education
  • Automobile
  • Sports
Search
Technology
  • Advertise
  • Advertise
Health
Entertainment
  • Home
  • Business
    • Business
  • News
  • Tech
  • Entertainment
  • Health
  • Education
  • Automobile
  • Sports
  • Advertise
  • Advertise
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved.
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Reading: Aarti Industries Delivers Volume-Led Growth in Q4; Sets Strong Foundation for FY26 with Strategic Expansions and Sustainability Focus
Share
Notification Show More
Font ResizerAa
Life Care NewsLife Care News
Font ResizerAa
  • Education
  • Automobile
  • Entertainment
  • News
  • Tech
  • Sports
Search
  • Home
  • Home
    • Home 1
    • Default Home 5
  • Categories
  • Categories
    • Tech
    • Entertainment
    • Automobile
    • Sports
    • Education
    • News
    • Health
  • Bookmarks
  • Bookmarks
  • More Foxiz
    • Sitemap
  • More Foxiz
    • Sitemap
Follow US
  • Advertise
  • Advertise
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
News

Aarti Industries Delivers Volume-Led Growth in Q4; Sets Strong Foundation for FY26 with Strategic Expansions and Sustainability Focus

PRNW Agency
Last updated: 09/05/2025 8:53 AM
PRNW Agency
Share
4 Min Read
Aarti Industries Delivers Volume-Led Growth in Q4; Sets Strong Foundation for FY26 with Strategic Expansions and Sustainability Focus
SHARE
Aarti Industries Delivers Volume-Led Growth in Q4; Sets Strong Foundation for FY26 with Strategic Expansions and Sustainability Focus

MUMBAI, India, May 8, 2025 /PRNewswire/ — Aarti Industries Limited (AIL), a leading global speciality chemicals company, today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2025. The company’s audited results were approved by the Board of Directors in a meeting held earlier today.

The company delivered volume-led growth, sequential improvement in profitability, and continued progress on key strategic and sustainability initiatives. On a consolidated basis, for the quarter, income from operations stood at ₹ 2214 Cr, compared to ₹ 2038 Cr in Q3 FY25 (‘previous quarter’). EBITDA stood at ₹ 266 Cr, compared to ₹ 236 Cr in the previous quarter. PAT stood at ₹ 96 Cr, compared to ₹ 46 Cr in the previous quarter.

FY25-26 has commenced on a confident note, supported by a steady demand recovery across key segments and robust execution of AIL’s long-term growth roadmap. The company remains well-positioned to leverage emerging opportunities across global markets through its diversified portfolio, innovation-led solutions, and strong customer relationships.

Financial Highlights (Q4 FY25)

- Advertisement -
  • Revenue: ₹ 2214 Cr, marking 9% QoQ growth
  • EBITDA: ₹ 266 Cr, up 13% QoQ, reflecting operating leverage and improved cost controls
  • PAT: ₹ 96 Cr, rising 109% sequentially on the back of better volumes and efficiency gains

Commenting on the performance, Mr. Suyog Kotecha, CEO and Executive Director, said:

“We are encouraged by the positive momentum across our businesses, particularly the recovery in core product volumes and the continued execution of our expansion and sustainability agenda. FY26 begins amid a volatile macroeconomic environment, US tariffs, geopolitical tensions, etc. With a strong pipeline of growth initiatives, we are focused on delivering consistent, value-led growth while strengthening our position as a global partner of choice.”

Business Highlights:

  • Strong volume recovery in Nitro Toluene, NCB, and Ethylation-based products, supported by capacity additions.
  • Sequential volume growth aided by refined pricing strategy and steady export demand; long-term offtake and spot flexibility maintained.
  • Hybrid renewable energy shift through two power purchase agreements; set to deliver cost and carbon savings by FY27.
  • Staggered commissioning of Zone IV projects in FY26 is expected to support multi-purpose manufacturing capabilities in FY27 and onwards.

FY24-25 Full-Year Performance

  • Revenue Growth: 13%
  • EBITDA: ₹ 1016 Cr, aligned with revised guidance
  • CAPEX: ₹ 1372 Cr focused on growth, energy efficiency, and innovation
  • Dividend: Final dividend of ₹ 1 per share (20% of face value of Rs. 5/- each) recommended by the Board

Awards and Recognition

- Advertisement -
  • AIL earned a coveted spot in the prestigious S&P Global Sustainability Yearbook 2025
  • Achieved significant recognition in environmental sustainability, securing Leadership Band “A” in CDP Climate Change and CDP Water Security for 2024

With a focus on operational excellence, margin recovery, and debt optimisation, AIL is positioned to enhance capital efficiency and execution momentum in FY26.

About AIL

Aarti Industries Limited (AIL) is one of the world’s leading speciality chemical companies, combining process chemistry with scale-up engineering competence. The Company ranks globally 1st – 4th position for 75% of its portfolio and is a “Partner of Choice” for various Major Global & Domestic Customers. At the heart of AIL’s operations is a dedication to sustainable development, seamlessly integrating environmental stewardship into its business model by leveraging cutting-edge technologies and a robust infrastructure to deliver solutions that balance economic growth with ecological responsibility. The Company’s commitment to innovative and sustainable practices and immense care for its people and the planet defines its path to success.

- Advertisement -

Website – www.aarti-industries.com/
LinkedIn- https://www.linkedin.com/company/aarti-industries/

Logo: https://mma.prnewswire.com/media/2610938/5146178/Aarti_Industries_Logo.jpg

 

View original content:https://www.prnewswire.com/in/news-releases/aarti-industries-delivers-volume-led-growth-in-q4-sets-strong-foundation-for-fy26-with-strategic-expansions-and-sustainability-focus-302450163.html

You Might Also Like

Tarsus to Participate in Upcoming Investor Conferences

U-Haul Growth Metros and Cities of 2024: Dallas is Top Metro for In-Migration

One year since the YOG Gangwon 2024: Celebrating Youth, Sport and Culture

DayOne Launches as an Independent Global Data Center Pioneer Following Series B Funding Closure

Kantar Group announces the proposed sale of Kantar Media

TAGGED:aartiacrossailannouncedchemicalscompanycomparedconsolidatedendedfinancialfourthfullglobalgrowthindia:industrieskeyleadinglimitedmarchmaymumbaipreviousquarterresultsspecialitystoodtodayyear₹

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.

By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share This Article
Facebook Twitter Copy Link Print
Share
Previous Article Cyient’s Expertise Acknowledged with Leadership Rankings in Nine Verticals by Zinnov Cyient’s Expertise Acknowledged with Leadership Rankings in Nine Verticals by Zinnov
Next Article Osstem, the World’s No. 1 in Implant Sales Volume, Pioneers India’s future of implantology with High-quality products and Clinical trainings Osstem, the World’s No. 1 in Implant Sales Volume, Pioneers India’s future of implantology with High-quality products and Clinical trainings

Stay Connected

FacebookLike
TwitterFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
Google NewsFollow
LinkedInFollow
MediumFollow
- Advertisement -

Latest News

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025
Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025
Health 18/05/2025
Brain Cancer Canada Awards ,000 Research Grant for Clinical Trial of Anti-Cancer Vaccine Targeting DIPG, the Most Aggressive Pediatric Brain Cancer
Brain Cancer Canada Awards $68,000 Research Grant for Clinical Trial of Anti-Cancer Vaccine Targeting DIPG, the Most Aggressive Pediatric Brain Cancer
Health 18/05/2025
Fractyl Health Unveils New Rejuva Smart GLP-1 Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025
Fractyl Health Unveils New Rejuva Smart GLP-1 Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025
Health 18/05/2025
Tessera Therapeutics Features New Preclinical Data Demonstrating Progress Across its In Vivo Gene WritingPrograms and Delivery Platform at the American Society of Gene and Cell Therapy 28th Annual Meeting
Tessera Therapeutics Features New Preclinical Data Demonstrating Progress Across its In Vivo Gene WritingPrograms and Delivery Platform at the American Society of Gene and Cell Therapy 28th Annual Meeting
Health 18/05/2025
//

We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Quick Link

  • About Us
  • Contact Us
  • Editorial Guidelines
  • Privacy Policy
  • Terms and Conditions

Top Categories

  • Automobile
  • Education
  • Entertainment
  • Health
  • News
  • Sports
  • Tech

Sign Up for Our Newsletter

Subscribe to our newsletter to get our newest articles instantly!

Life Care NewsLife Care News
Follow US
Copyright © 2015 - 2024 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..

Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?